Last updated: May 6, 2024
Sponsor: University of British Columbia
Overall Status: Active - Recruiting
Phase
N/A
Condition
Multiple Sclerosis
Scar Tissue
Memory Loss
Treatment
N/AClinical Study ID
NCT01118130
H10-00494
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: Cases and controls must have
- definite MS (Poser or McDonald criteria)
- relapsing-remitting or secondary-progressive disease course
- Prescribed a beta-interferon as their immunomodulatory drug for MS
Exclusion
Exclusion Criteria:
- primary-progressive MS
- an elevated liver test result within 6 months of starting beta-interferon treatment
- presence of a co-morbidity that is a known risk-factor for liver injury
Study Design
Total Participants: 300
Study Start date:
June 01, 2010
Estimated Completion Date:
May 31, 2025
Study Description
Connect with a study center
MS Clinic UBC Hospital
Vancouver, British Columbia V6T 2B5
CanadaActive - Recruiting
Winnipeg Health Sciences Centre
Winnipeg, Manitoba
CanadaCompleted
Dalhousie MS Research Unit
Halifax, Nova Scotia
CanadaSite Not Available
London Health Sciences Centre MS clinic
London, Ontario
CanadaSite Not Available
Hôpital Notre-Dame MS clinic
Montréal, Quebec
CanadaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.